What is PreciseDx?
PreciseDx is a pioneering company focused on cancer risk stratification, uniquely providing patient-specific risk information through the analysis of morphology features. This capability enables more personalized treatment strategies and improved patient outcomes, positioning PreciseDx at the forefront of precision medicine in oncology.
How much funding has PreciseDx raised?
PreciseDx has raised a total of $42.5M across 3 funding rounds:
Series A
$10.8M
Series B
$20.7M
Other Financing Round
$11M
Series A (2022): $10.8M with participation from Mount Sinai Health System, Agile Technologies, and Merck GHI
Series B (2024): $20.7M led by Eventide Asset Management, Labcorp, and Quest Diagnostics
Other Financing Round (2025): $11M supported by Labcorp, Quest Diagnostics Inc, Eventide Asset Management, Philip Ventures, GenHenn Capital, and Merck & Co
Key Investors in PreciseDx
Mount Sinai Health System
Mount Sinai Health System is an integrated health system dedicated to providing distinguished care, conducting transformative research, and advancing biomedical education. Their involvement suggests a strong alignment with clinical application and research validation.
Agile Technologies
Agile Technologies is a technology service firm focused on building durable relationships and delivering powerful business results through technology. Their participation may indicate a strategic interest in the technological underpinnings of PreciseDx's platform.
Merck GHI
Merck GHI's involvement, though with an unspecified domain, points to potential strategic backing from a major player in the global healthcare and pharmaceutical industry, likely focusing on therapeutic advancements.
What's next for PreciseDx?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for PreciseDx. This capital is expected to accelerate product development, expand market reach, and further solidify its leadership in providing advanced diagnostic tools for personalized cancer care. The company is poised to leverage this backing to drive innovation and enhance its offerings to healthcare providers and patients.
See full PreciseDx company page
